Illumina News and Research

RSS

Finding right balance between high-throughput sequencing and related bioinformatics analysis

Balancing high-throughput sequencing and related bioinformatics analysis between a research group’s internal efforts and specialized service providers can both speed results to difficult biological questions and provide cost-effective access to the latest technology, says Eureka Genomics (EG). The company’s unique capabilities and services and how they can help in “Finding the Right Balance” will be the topic of discussion at a “Java and Jive” session on Wednesday March 17, 8:15 am at the Now-Generation Sequencing conference being held at the Hilton San Diego Resort in San Diego, CA.

17 Mar 2010

Illumina announces enhancement to OmniExpress BeadChip

Illumina, Inc. today unveiled its new HumanOmniExpress+ Custom BeadChip (OmniExpress+), an enhancement to the recently announced OmniExpress BeadChip that allows for the addition of up to 200,000 custom variants for a total of >900k variants per sample. OmniExpress+ leverages the proven iSelect custom genotyping infrastructure to provide researchers with unlimited flexibility in adding custom content for disease or pathway-specific markers, rare variants from the 1,000 Genomes Project, or panels for fine-mapping onto the industry’s most optimal set of SNPs.

From Illumina, Inc. 16 Mar 2010

CLC bio releases groundbreaking whole-genome de novo assembler

Today, CLC bio released a groundbreaking whole-genome de novo assembler that will assemble genomes of any size, including human and plant genomes on a single workstation computer. Equally important, CLC bio’s de novo assembler is the first assembler that enables molecular biologists to set up, adjust, and run their large genome de novo assemblies through a graphical user-interface.

16 Mar 2010

Illumina sequences DNA of American actress Glenn Close

Illumina, Inc. today announced that it has sequenced the DNA of American actress Glenn Close, the first publicly named female to have her DNA sequenced to full coverage.

From Illumina, Inc. 11 Mar 2010

Orchid Cellmark reports 21% increase in total revenues for fourth-quarter 2009

Orchid Cellmark Inc., a leading international provider of identity DNA testing services, today reported its financial results for the fourth quarter and full year of 2009.

11 Mar 2010

Genomatix systems utilized to analyze cis and epigenetic elements that control reproductive events

The C.S. Mott Center for Human Growth and Development, Department of Obstetrics and Gynecology, at the Wayne State University School of Medicine, in collaboration with the Center for Molecular Medicine and Genetics, the Karmanos Cancer Institute and the Institute for Environmental Health Sciences, installed a Genomatix Mining Station and a Genomatix Genome Analyzer last year at their labs in Detroit, MI in order to support the analysis of Next Generation Sequencing (NGS) data.

11 Mar 2010

Study: Bacteria, fungi and other microbes live in our gut are essential contributors to good health

The thousands of bacteria, fungi and other microbes that live in our gut are essential contributors to our good health. They break down toxins, manufacture some vitamins and essential amino acids, and form a barrier against invaders. A study published today in Nature shows that, at 3.3 million, microbial genes in our gut outnumber previous estimates for the whole of the human body.

4 Mar 2010

Agilent Technologies announces new multiplexing capability in SureSelect Target Enrichment System

Agilent Technologies Inc. today announced that its Agilent SureSelect Target Enrichment System supports multiplexed DNA sequencing of 12 to 16 samples per lane depending on the next-generation sequencing platform, reducing costs and increasing throughput up to 16-fold.

25 Feb 2010

Fluidigm releases amplicon tagging protocol for Illumina GA II next-generation sequencer

Fluidigm Corporation today announced the release of its amplicon tagging protocol for the Illumina GA II next-generation sequencer. The 48.48 Access Array integrated fluidic circuit (IFC) allows Illumina GA II users to automatically prepare sequencing-ready libraries from 48 individual samples at a time, for as little as $7 (U.S.) per sample.

10 Feb 2010

New England Biolabs to supply Wellcome Trust Sanger Institute next-generation sequencing library construction reagents

As an important supplier to the Wellcome Trust Sanger Institute, New England Biolabs is pleased to announce that the Sanger Institute will use New England Biolabs as one of its suppliers for next-generation sequencing library construction reagents.

From New England Biolabs 5 Feb 2010

Study finds link between genes that regulate maternal inflammatory response, bacterial vaginosis and preterm delivery

In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in Chicago, researchers will show the use of haplotype tagging (hap-tag) single-nucleotide polymorphisms (SNPs) to study the relationship between genetic predispositions, an environmental factor - bacterial vaginosis, and preterm birth.

4 Feb 2010

Oxford Nanopore Technologies raises $28M in new funding

Oxford Nanopore Technologies Ltd., a privately held company that is developing a disruptive technology platform for the electronic, label-free analysis of single molecules, today announced that it has raised £17.4 million ($28 million) in new funding.

From Oxford Nanopore Technologies 1 Feb 2010

Illumina launches HumanOmniExpress BeadChip for GWAS

Illumina, Inc. today announced the HumanOmniExpress BeadChip (OmniExpress), the newest addition to the Omni family of microarrays for genome-wide association studies (GWAS).

From Illumina, Inc. 11 Jan 2010

LadaTech files patent infringement lawsuit against Illumina

LadaTech announced today that it has served its complaint upon Illumina, Inc. in its lawsuit for patent infringement in the United States District Court for the District of Delaware. LadaTech is jointly owned by GlaxoSmithKline and IP Finance Holdings.

From Illumina, Inc. 22 Dec 2009

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

The Burrill Biotech Select Index managed to claw back almost half the value it lost in October. The Select's gain of 4.5 percent mirrored what was also an excellent month for the general markets with the Dow up 6.5 percent and the NASDAQ up 4.8 percent in value.

2 Dec 2009

Illumina's Board of Directors authorize a new stock repurchase program

Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.

From Illumina, Inc. 25 Nov 2009

EraGen Biosciences to have access to Illumina’s BeadXpress platform

EraGen Biosciences Inc., a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market, and Illumina Inc., a global company that develops, manufactures and markets integrated systems for analysis of genetic variation and biological function, today announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements.

From Illumina, Inc. 23 Nov 2009